Selective androgen receptor modulators, often shortened to SARMs like rad 140 , have generated significant attention in both the scientific community and among fitness enthusiasts. Two of the most prominent compounds in this category are RAD 140 (Testolone) and RAD 150 (its benzoate ester modified version). Together, they represent one of the most discussed debates in performance and medical research: RAD 150 vs RAD 140.
Both substances act on androgen receptors in muscle and bone tissue, mimicking certain anabolic effects traditionally associated with anabolic steroids, but with greater tissue selectivity. While they are not FDA approved for human consumption, they have been the subject of preclinical studies, clinical trials, and animal studies designed to evaluate their efficacy, safety, and potential medical use.
This article will cover each compound individually, followed by a detailed comparison to highlight differences in their potency, half life, safety concerns, and potential treatment applications.
What is RAD 140 (Testolone)?
RAD 140, also known as Testolone, is one of the most widely studied selective androgen receptor modulators. It was originally developed as a potential treatment for muscle wasting conditions, osteoporosis, and even certain cancers such as breast cancer and prostate cancer. Unlike anabolic steroids, RAD 140 was designed to achieve anabolic effects in muscle and bone while minimizing risks to other organs.
For a detailed look at how peptide therapy can complement androgen receptor research, visit TRTPeptide.com for insight into hormone balance and muscle recovery support strategies.
Mechanism of Action
RAD 140 works by binding to androgen receptors, the same receptors activated by natural testosterone. Its tissue selectivity means that it primarily affects muscle and skeletal tissue, theoretically reducing safety concerns linked to the liver or reproductive organs. This makes it distinct from traditional anabolic steroid use.
Research and Trials
Although not FDA approved, RAD 140 has appeared in preclinical studies, clinical studies, and even limited human trials. Researchers have investigated its role in preserving bone mineral density in patients with osteoporosis, as well as its potential to act as an alternative to androgen therapy.
A systematic review of existing data suggests promising results, though much of the evidence comes from animal studies and small-scale clinical trials. That being said, we’ve done a deep dive on the anecdotal RAD 150 before and after results from users of both RAD 150 and RAD 140.
Potential Benefits
- Muscle growth and preservation in subjects with muscle-wasting disorders
- Improved athletic performance due to anabolic-like effects
- Possible medical use in breast cancer or prostate cancer therapies
- Enhancement of bone mineral density in osteoporosis research
Potential Side Effects
While early research suggests fewer risks than anabolic steroids, some potential side effects have been documented. These include mood swings, hormonal suppression of natural testosterone, and general safety concerns regarding hepatotoxicity.
What is RAD 150?
RAD 150 is essentially a modified version of RAD 140, created by attaching a benzoate ester. This chemical adjustment results in a longer half life, making RAD 150 more potent in terms of potency and duration. The development of RAD 150 aimed to create a compound with all the beneficial effects of RAD 140 while improving dose stability.
Mechanism of Action
Like its predecessor, RAD 150 binds to selective androgen receptors, producing anabolic-like activity in muscle and skeletal tissue. However, due to its longer half life, RAD 150 maintains more stable blood concentrations in users, reducing the frequency of administration and potentially enhancing efficacy.
Research Status
Compared to RAD 140, RAD 150 has far fewer clinical trials or human data available. Most insights come from in vitro research, animal studies, or theoretical pharmacological models. While researchers believe it may share many properties with RAD 140, more clinical and human trials are needed before any medical use can be determined.
To understand how peptides may assist in recovery and tissue regeneration following SARM research cycles, see PeptideForMuscleGrowth.com for an overview of muscle repair and systemic recovery mechanisms.
Potential Benefits
- Extended half life compared to RAD 140
- Theoretical improvement in muscle retention and growth
- Reduced frequency of dose administration due to stability
- Potential to contribute to systemic recovery in certain patients
Potential Side Effects
Since RAD 150 is newer, the list of potential side effects is speculative. Risks may occur similar to RAD 140, including:
- Suppression of natural testosterone
- Hormonal imbalance, including effects on estrogen
- Possible hepatotoxicity
- General safety concerns due to lack of human consumption studies
Related Article – RAD 150 Dosage: Understanding Cycles, Benefits, and Considerations
Key Comparisons Between RAD 150 and RAD 140
To simplify the discussion, the following chart highlights the major comparison points between these 2 SARMS:
| Feature | RAD 140 (Testolone) | RAD 150 |
|---|---|---|
| Classification | Selective androgen receptor modulator | Modified version of RAD 140 with benzoate ester |
| Primary Uses | Studied for muscle wasting conditions, osteoporosis, breast cancer, prostate cancer | Experimental compound for muscle growth and extended performance |
| Half Life | Estimated 16–20 hours | Extended due to esterification (longer half life) |
| Benefits | Supports muscle retention, improves bone mineral density, may aid in certain medical applications | Improved potency, fewer required doses, possible enhanced efficacy |
| Research | Appears in multiple clinical trials, preclinical studies, and some human data | Limited research, mostly in vitro and animal studies |
| Risks / Side Effects | Potential side effects include hormonal suppression, mood swings, possible hepatotoxicity | Speculative risks; may mimic RAD 140’s safety concerns but data is lacking |
| Medical Use | Investigated for androgen therapy and as a potential treatment in oncology | No established medical use yet |
| Legal / Regulatory Status | Not FDA approved, listed as prohibited by the World Anti Doping Agency | Also not FDA approved, similarly restricted |
| Users | Bodybuilding communities, patients in trials | Mainly researchers and experimental subjects |
Clinical Trials and Research Findings
RAD 140
- Has undergone clinical trials investigating its role in muscle wasting conditions.
- Clinical studies highlight its ability to improve lean mass in patients.
- Some case reports have noted suppression of natural testosterone and mild hepatotoxicity.
RAD 150
- Very limited human data is available.
- Most findings come from preclinical studies and in vitro testing.
- Its efficacy is theorized rather than conclusively proven in subjects.
Both compounds remain investigational, with future development depending heavily on more structured clinical evaluations.
Potential Medical Applications
RAD 140
Its medical use has been tied to:
- Breast cancer research as a potential treatment option
- Prostate cancer therapies with more targeted activity
- Osteoporosis and improvement in bone mineral density
- Adjunct androgen therapy for patients unable to tolerate anabolic steroid use
RAD 150
- Still largely hypothetical in terms of medical applications
- May eventually be studied for muscle wasting conditions and systemic recovery
- Lacks clinical trials or human trials to confirm any therapeutic efficacy
Risks, Safety, and Regulatory Landscape
Both RAD 140 and RAD 150 are not FDA approved and remain classified as substances intended only for research. They are banned in professional sports by the World Anti Doping Agency due to their ability to enhance athletic performance.
Potential safety concerns include:
- Suppression of natural testosterone production
- Possible hepatotoxicity
- Psychological effects such as mood swings or fatigue
- Risks of unregulated bodybuilding use without medical oversight
Because human consumption outside clinical settings is unapproved, long-term review of their safety and efficacy remains incomplete.
RAD-150 vs RAD-140: Which Is Better?
From a research standpoint, RAD 140 currently has more human data, documented clinical trials, and medical potential treatment discussions. On the other hand, RAD 150 offers a longer half life and possibly greater potency, but lacks human trials and carries greater uncertainty regarding risk.
For researchers, both compounds provide insight into the development of future selective androgen receptor modulators. For users, the lack of FDA approval, unclear medical use, and unresolved safety concerns make both options high-risk.
Frequently Asked Questions
Will RAD140 give you gyno?
Gyno (gynecomastia) typically occurs when there is an imbalance between testosterone and estrogen. RAD140 itself does not aromatize into estrogen the way anabolic steroids can, so the direct risk is considered low. However, since RAD140 can suppress natural testosterone, rebound increases in estrogen may occur when coming off a cycle. This secondary effect could contribute to gyno risk if not managed properly.
Is RAD140 hard on the liver?
Some case reports and early clinical data suggest RAD140 may cause hepatotoxicity, meaning it could be stressful on the liver. Elevated liver enzymes have been observed in certain subjects during research. While it may not be as liver-toxic as oral anabolic steroids, safety concerns remain, and long-term human trials are lacking.
Does RAD140 enlarge the prostate?
RAD140 was actually investigated as a potential treatment for prostate cancer because of its tissue selectivity. Unlike anabolic steroid use, it was designed not to overstimulate prostate tissue. Current preclinical studies suggest it does not significantly enlarge the prostate, though suppression of natural testosterone could indirectly affect hormone balance. More human data is needed.
Does RAD140 affect DHT?
RAD140 does not directly convert into dihydrotestosterone (DHT). However, because it binds strongly to androgen receptors, it may influence DHT pathways indirectly by reducing the body’s production of natural testosterone. This suppression can lower normal androgen conversion rates, though RAD140 itself is not metabolized into DHT.
Conclusion
The debate of RAD 150 vs RAD 140 underscores the growing interest in selective androgen receptor modulators as alternatives to anabolic steroids. RAD 140 remains the more documented compound, with evidence from clinical trials, preclinical studies, and limited human data. RAD 150, while promising as a modified version with a benzoate ester, needs far more research before its efficacy and safety can be fully understood.
Both substances highlight how researchers continue to explore SARMs for muscle growth, bodybuilding bone mineral density, and even cancer treatment. However, without FDA approval, they remain experimental, raising regulatory and safety concerns. Future systematic review and clinical development will determine whether these compounds transition from experimental substances into viable medical use therapies.